These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31571826)

  • 21. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
    Stark AD; Jordan S; Allers KA; Bertekap RL; Chen R; Mistry Kannan T; Molski TF; Yocca FD; Sharp T; Kikuchi T; Burris KD
    Psychopharmacology (Berl); 2007 Feb; 190(3):373-82. PubMed ID: 17242925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine.
    Choi YK; Adham N; Kiss B; Gyertyán I; Tarazi FI
    CNS Spectr; 2017 Dec; 22(6):484-494. PubMed ID: 28059046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
    Gründer G
    Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.
    Kiss B; Laszlovszky I; Horváth A; Némethy Z; Schmidt E; Bugovics G; Fazekas K; Gyertyán I; Agai-Csongor E; Domány G; Szombathelyi Z
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov; 378(5):515-28. PubMed ID: 18551280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generalization of serotonin (5-HT)1A agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminative stimuli elicited by PD128,907 and 7-OH-DPAT.
    Dekeyne A; Rivet JM; Gobert A; Millan MJ
    Neuropharmacology; 2001 Jun; 40(7):899-910. PubMed ID: 11378160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and Pharmacology of the enantiomers of the potential atypical antipsychotic agents 5-OMe-BPAT and 5-OMe-(2,6-di-OMe)-BPAT.
    Homan EJ; Copinga S; Unelius L; Jackson DM; Wikström HV; Grol CJ
    Bioorg Med Chem; 1999 Jul; 7(7):1263-71. PubMed ID: 10465402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The novel atypical antipsychotic cariprazine demonstrates dopamine D
    Delcourte S; Ashby CR; Rovera R; Kiss B; Adham N; Farkas B; Haddjeri N
    CNS Neurosci Ther; 2018 Dec; 24(12):1129-1139. PubMed ID: 29729086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors.
    Tadori Y; Forbes RA; McQuade RD; Kikuchi T
    Eur J Pharmacol; 2011 Oct; 668(3):355-65. PubMed ID: 21816144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacology profile of F17464, a dopamine D
    Cosi C; Martel JC; Auclair AL; Collo G; Cavalleri L; Heusler P; Leriche L; Gaudoux F; Sokoloff P; Moser PC; Gatti-McArthur S
    Eur J Pharmacol; 2021 Jan; 890():173635. PubMed ID: 33065094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cariprazine:New dopamine biased agonist for neuropsychiatric disorders.
    De Deurwaerdère P
    Drugs Today (Barc); 2016 Feb; 52(2):97-110. PubMed ID: 27092339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
    Tadori Y; Kikuchi T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model.
    Duric V; Banasr M; Franklin T; Lepack A; Adham N; Kiss B; Gyertyán I; Duman RS
    Int J Neuropsychopharmacol; 2017 Oct; 20(10):788-796. PubMed ID: 28531264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
    Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F
    Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term administration of cariprazine increases locus coeruleus noradrenergic neurons activity and serotonin
    El Mansari M; Ebrahimzadeh M; Hamati R; Iro CM; Farkas B; Kiss B; Adham N; Blier P
    J Psychopharmacol; 2020 Oct; 34(10):1143-1154. PubMed ID: 32684081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
    Keks N; Hope J; Schwartz D; McLennan H; Copolov D; Meadows G
    CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors.
    Tadori Y; Forbes RA; McQuade RD; Kikuchi T
    Eur J Pharmacol; 2008 Nov; 597(1-3):27-33. PubMed ID: 18831971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.
    Corbin AE; Meltzer LT; Ninteman FW; Wiley JN; Christoffersen CL; Wustrow DJ; Wise LD; Pugsley TA; Heffner TG
    Neuropharmacology; 2000 Apr; 39(7):1211-21. PubMed ID: 10760363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study.
    Earley W; Burgess MV; Rekeda L; Dickinson R; Szatmári B; Németh G; McIntyre RS; Sachs GS; Yatham LN
    Am J Psychiatry; 2019 Jun; 176(6):439-448. PubMed ID: 30845817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A positron emission tomography occupancy study of brexpiprazole at dopamine D
    Girgis RR; Forbes A; Abi-Dargham A; Slifstein M
    Neuropsychopharmacology; 2020 Apr; 45(5):786-792. PubMed ID: 31847007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.